GlassScriptPhysician profile
Jamie Shriver
NPI 1184221624
$3,187.07
in general payments reported to CMS, 2019-2025
22 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $615 · 2022: $1,245 · 2023: $689 · 2024: $292 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $901.05 | 2021-2023 | Intellis Adaptivestim, Synchromedii |
| Abbvie INC. | $728.59 | 2021-2024 | |
| Novo Nordisk INC | $262.53 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Biohaven Pharmaceutical Holding Company LTD. | $184.26 | 2022 | |
| Lilly USA, LLC | $177.70 | 2022-2025 | Zepbound, Mounjaro |
| Chiesi USA, INC. | $112.11 | 2025 | Myalept |
| Lundbeck LLC | $109.14 | 2022-2023 | Vyepti |
| Collegium Pharmaceutical, INC. | $105.45 | 2022-2023 | Xtampza, Belbuca |
| Amgen INC. | $96.86 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $79.58 | 2021 | |
| Horizon Therapeutics Plc | $63.96 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $58.52 | 2024-2025 | Imcivree |
| Ibsa Pharma INC. | $54.95 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $48.36 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $43.52 | 2024-2025 | Contrave |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $34.92 | 2022 | |
| Pfizer INC. | $30.96 | 2023 | |
| Merz North America, INC. | $24.54 | 2021 | |
| Tersera Therapeutics LLC | $21.07 | 2023 | Prialt |
| Merz Pharmaceuticals, LLC | $18.86 | 2023 | Xeomin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.79 | 2023 | Relistor |
| Redhill Biopharma INC. | $14.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Shriver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.